9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Part of paid clinical trials in Fairway, Kansas.

Sponsor
Anwaar Saeed
Study ID
NCT05239182
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 9-ING-41 — DRUG
    9-ING-41 is a small molecule potent selective GSK-3β inhibitor
  • Retifanlimab — DRUG
    Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.
  • Gemcitabine — DRUG
    cytotoxic chemotherapy agent
  • Abraxane — DRUG
    cytotoxic chemotherapy agent

Study Details

This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease progression.

Key Dates

Start date
Jan 26, 2022
Status verified
Jun 2025
Primary completion
Dec 20, 2022
Completion
Feb 4, 2024

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 9-ING-41 plus Retifanlimab plus Gem/Abraxane
    * intravenous (IV) infusion of nab-paclitaxel at a dose of 125 mg per square meter, followed by an infusion of gemcitabine according to the gemcitabine label at a dose of 1000 mg per square meter, on days 1, 8, 15 of a 28-day cycle. * Retifanlimab 500 mg IV on day 1 of a 28-day cycle. (Retifanlimab will be administered following gemcitabine/nab-paclitaxel.) * 9-ING-41 administered at a dose of 9.3 mg/kg by IV infusion twice weekly on Days 1 and 4 of each week of a 28-day cycle. (9-ING-41 will be administered following retifanlimab.)

Primary Outcome Measure

Disease Control Rate (DCR) [ Time Frame: Up to approximately 11 months from baseline ]

Locations (2)

FacilityCityStateZIPSite coordinators
Kansas University Cancer CenterFairwayKansas66205-
UPMC Hillman Cancer CenterPittsburghPennsylvania15232-

Find similar trials in Fairway, KS

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Kansas University Cancer Center· Fairway, KSUPMC Hillman Cancer Center· Pittsburgh, PA

Related Studies